Legislation barring federally-funded medical providers from signing contracts with foreign adversary biotech companies has been introduced in both the Senate and the house of Representatives.
The Prohibiting Foreign Access to American Genetic Information Act of 2024 would ban all biotechnology companies that are owned or controlled by a foreign adversary, such as the Chinese Communist Party (CCP), and whose business practices threaten national security, from receiving U.S. taxpayer dollars through federal contracts, grants, and loans.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
If you are a current subscriber, and had an account on our previous site, you already have an account. If you have not yet logged into our new site, click here to reset your password.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
